$73.71
N/A
Last update: Nov 12, 4:00 PM
Corcept Therapeutics Inc
CORTNASDAQ
Corcept Therapeutics fell 2.7% from $75.75 to $73.71, behind the S&P 500's +12.7%. Its worst day was Dec 31 (−50.4%), and its low came Mar 13 at $32.15.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Corcept Therapeutics shares fell 50.4%, while the S&P 500 fell 0.7%.
−50.4%, the year's worst day, on 20M shares, the year's heaviest volume · S&P 500 −0.7%
Story events cover the past 12 months · Times ET
Data demonstrate a 35 percent reduction in the risk of deathBoth dual primary endpoints (progression-free and overall survival) were met, without the need for biomarker selection and without increased safety
+13.7% · S&P 500 +0.5%
EPS of $0.20 missed the $0.31 estimate on $202.1M revenue (est. $254.7M); FY revenue guidance of $900.0M–$1.0B against the $993.4M consensus.
−0.7% · S&P 500 +0.8%
Corcept Therapeutics closed at its lowest level of the year, 57.6% below where the year started.
−0.7% · S&P 500 −0.6%
Corcept Therapeutics shares rose 19.7%, while the S&P 500 rose 0.6%.
+19.7% · S&P 500 +0.6%
EPS of $-0.30 missed the $-0.17 estimate on $164.9M revenue (est. $183.8M); FY revenue guidance of $950.0M–$1.1B against the $931.0M consensus.
+10.5% · S&P 500 +0.3%
EPS of $0.36 beat the $0.02 estimate on $256.1M revenue (est. $219.3M); FY revenue guidance of $1.1B–$1.2B against the $1.0B consensus.
+27.3%, the year's best day · S&P 500 +1.7%
Corcept Therapeutics closed at its highest level of the year, 63.1% above where the year started.
+0.3% · S&P 500 +0.3%
Corcept Therapeutics shares fell 20.1%, while the S&P 500 fell 0.5%.
−20.1% · S&P 500 −0.5%
EPS of $1.01 beat the $0.81 estimate on $340.5M revenue (est. $334.9M); FY revenue guidance of $1.1B–$1.2B against the $1.1B consensus.
−3.3% · S&P 500 +1.7%
Where it ended: a close of $73.71 on Nov 12, 2026. Up next: Q4 2026 earnings on Feb 23, 2027 (EPS est. $1.14, revenue est. $394.9M).
Nothing in the past 12 months.
All CORT dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CORT and SPY from Benzinga historical bars. Not investment advice.
